Novel immunopotentiators are essential for advancingour understandingof immune receptor crosstalk and for addressing infectious diseases.Previous studies have suggested that coactivation of nucleotide-bindingoligomerization domain-containing protein 2 (NOD2) and Toll-like receptor4 (TLR4) can synergistically enhance the immune response. Here, TLR4 is linked to infectious disease.